Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AtheroGenics has completed enrollment of its double-blind, placebo-controlled Phase III ANDES clinical trial of AGI-1067, an oral anti-inflammatory antioxidant agent in development for the treatment of type II diabetes.
Subscribe to our email newsletter
The ANDES (AGI-1067 as a novel antidiabetic agent evaluation study) trial has enrolled 999 patients with type II diabetes at approximately 150 clinical sites in the US, South Africa, India and eastern Europe. AtheroGenics expects to announce the results from a pre-planned interim analysis in the second quarter of 2008, with final results due in the second half of 2008.
Russell Medford, president and CEO of AtheroGenics, said: “We are pleased to have completed enrollment of the ANDES study on schedule. With the compound’s unique anti-inflammatory and antioxidant approach to treating diabetes, we believe that AGI-1067, if proven safe and effective, could improve the treatment of the many diabetic patients for whom current therapies are inadequate.”